Is this critically ill patient immunocompromised?

Intensive Care Medicine

Volumn 42, Issue 6, 2016, Pages 1051-1054

  Pène, Frédéric ^a,b   Pickkers, Peter ^c   Hotchkiss, Richard S ^d  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; CORTICOSTEROID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 3; INTERLEUKIN 7; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ALCOHOLISM; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED INFECTION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; GLUCOSE INTOLERANCE; HEMATOLOGIC MALIGNANCY; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOTHERMIA; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION SENSITIVITY; INFLAMMATION; INTENSIVE CARE UNIT; LABORATORY TEST; LACTIC ACIDOSIS; LETHARGY; LIVER FAILURE; LYMPHOCYTE COUNT; MALNUTRITION; MENTAL INSTABILITY; MESENCHYMAL STEM CELL; MULTIPLE ORGAN FAILURE; NEOPLASM; OPPORTUNISTIC INFECTION; SECONDARY INFECTION; SEPSIS; SHOCK; SYSTEMIC MYCOSIS; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS REACTIVATION; WOUND INFECTION; IMMUNOLOGY; INTENSIVE CARE; RESPIRATORY DISTRESS SYNDROME, ADULT;

ADJUVANTS, IMMUNOLOGIC; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS;

EID: 84949008849     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-4161-y     Document Type: Editorial

References (18)

1. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150
2. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P (2013) Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 187:1287–1293
3. Daviaud F, Grimaldi D, Dechartres A, Charpentier J, Geri G, Marin N, Chiche JD, Cariou A, Mira JP, Pene F (2015) Timing and causes of death in septic shock. Ann Intensive Care 5:58
4. Petersen L, Andersen PK, Sorensen TI (2010) Genetic influences on incidence and case-fatality of infectious disease. PLoS One 5:e10603
5. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, Sharifi N, Janssen-Megens EM, Ter Huurne M, Mandoli A, van Schaik T, Ng A, Burden F, Downes K, Frontini M, Kumar V, Giamarellos-Bourboulis EJ, Ouwehand WH, van der Meer JW, Joosten LA, Wijmenga C, Martens JH, Xavier RJ, Logie C, Netea MG, Stunnenberg HG (2014) Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345:1251086
6. Drewry AM, Fuller BM, Skrupky LP, Hotchkiss RS (2015) The presence of hypothermia within 24 hours of sepsis diagnosis predicts persistent lymphopenia. Crit Care Med 43:1165–1169
7. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz F, Milder M, Louis D, Chiche JD, Mira JP, Lantz O, Pene F (2014) Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med 40:192–201
8. Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862–874
9. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, Pachot A, Brooks TL, Deych E, Shannon WD, Green JM, Storch GA, Hotchkiss RS (2014) Reactivation of multiple viruses in patients with sepsis. PLoS One 9:e98819
10. Asehnoune K, Roquilly A, Abraham E (2012) Innate immune dysfunction in trauma patients: from pathophysiology to treatment. Anesthesiology 117:411–416
11. Manez R, Kusne S, Linden P, Gonzalez-Pinto I, Bonet H, Kramer D, Fung JJ, Starzl TE (1994) Temporary withdrawal of immunosuppression for life-threatening infections after liver transplantation. Transplantation 57:149–151
12. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, Payen D (2009) Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 37:2746–2752
13. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180:640–648
14. Demaret J, Villars-Mechin A, Lepape A, Plassais J, Vallin H, Malcus C, Poitevin-Later F, Monneret G, Venet F (2014) Elevated plasmatic level of soluble IL-7 receptor is associated with increased mortality in septic shock patients. Intensive Care Med 40:1089–1096
15. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P, Monneret G (2010) Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 36:1859–1866
16. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G (2012) IL-7 restores lymphocyte functions in septic patients. J Immunol 189:5073–5081
17. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X (2013) The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 17:R8
18. Hotchkiss RS, Moldawer LL (2014) Parallels between cancer and infectious disease. N Engl J Med 371:380–383